Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Organic / Comparable Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q4 2025
-18.1%
Period ended Dec 31, 2025
Change on a year earlier
-17.1 pts
-1.0% in Q4 2024
History
27 quarters
Since Q1 2019
Sources
27
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Organic / Comparable Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | -18.1% | -17.1 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | -27.7% | -24.7 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | -6.8% | +13.0 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | -16.1% | +22.6 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | -1.0% | +48.2 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | -3.0% | +55.9 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | -19.8% | +52.5 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | -38.7% | – | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | -49.2% | -17.6 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | -58.9% | -63.8 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | -72.3% | -156.9 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q4 2022 | Dec 31, 2022 | -31.6% | -41.4 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | 4.9% | -138.4 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | 84.6% | -93.0 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | 60.8% | -234.2 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | 9.8% | -319.2 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | 143.3% | +60.3 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | 177.6% | +166.6 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 295.0% | +289.6 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | 329.0% | +326.3 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | 83.0% | +82.2 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | 11.0% | +8.2 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | 5.4% | +6.8 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | 2.7% | – | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | 0.8% | – | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | 2.8% | – | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | -1.4% | – | SEC Filing (0001104659-19-021809) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Rapid Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — ID NOW, BinaxNOW, Panbio) — Organic / Comparable Sales Growth (%) (%), quarterly Q1 2019–Q4 2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-rapid-leg-yoy-org
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.